Ignaty Leshchiner, PhD
2024 Toffler Scholar | Assistant Professor of Medicine and Computational Biomedicine, Chobanian and Avedisian Boston University School of Medicine
FIND ME ON
Biography
Ignaty Leshchiner’s scientific worldview, shaped early by his Moscow roots and family history, inspires respect and admiration for his diverse influences. Born in Moscow to a family deeply rooted in scholarship, he grew up surrounded by ideas, language, and analytical thinking. His grandparents were physicists. One of the grandfathers served as a professor of economics. His father trained as a mathematician and spent his career in computer science, while pursuing a parallel passion for linguistics, particularly Native American languages.
Science and inquiry were not abstract concepts in Leshchiner’s childhood. They formed the background of everyday life.
In the early 1990s, as political and social landscapes shifted, Leshchiner’s family moved to the United States. He was seven years old when he first arrived in Boston. Over the next several years, his family traveled back and forth between Russia and the United States as his father worked in academia and later in industry. Leshchiner completed parts of his early education in both countries, learning to adapt across cultures, languages, and educational systems.
Eventually, his parents settled in California, where Leshchiner attended middle and high school. The experience of growing up across continents shaped his perspective early. He learned to navigate complexity, uncertainty, and change, traits that would later define his scientific approach.
"I was always interested in science in some form," he recalls. "Biology, chemistry, physics. I wanted to understand how things worked."
Biography
Ignaty Leshchiner’s scientific worldview, shaped early by his Moscow roots and family history, inspires respect and admiration for his diverse influences. Born in Moscow to a family deeply rooted in scholarship, he grew up surrounded by ideas, language, and analytical thinking. His grandparents were physicists. One of the grandfathers served as a professor of economics. His father trained as a mathematician and spent his career in computer science, while pursuing a parallel passion for linguistics, particularly Native American languages.
Science and inquiry were not abstract concepts in Leshchiner’s childhood. They formed the background of everyday life.
In the early 1990s, as political and social landscapes shifted, Leshchiner’s family moved to the United States. He was seven years old when he first arrived in Boston. Over the next several years, his family traveled back and forth between Russia and the United States as his father worked in academia and later in industry. Leshchiner completed parts of his early education in both countries, learning to adapt across cultures, languages, and educational systems.
Eventually, his parents settled in California, where Leshchiner attended middle and high school. The experience of growing up across continents shaped his perspective early. He learned to navigate complexity, uncertainty, and change, traits that would later define his scientific approach.
“I was always interested in science in some form,” he recalls. “Biology, chemistry, physics. I wanted to understand how things worked.”
Research Focus
As a student, Leshchiner gravitated toward the life sciences. His first formal exposure to biology came through extracurricular microscopy classes in Moscow, where he examined cells and tissues firsthand. Gardening projects and hands-on observation reinforced his interest in living systems. By high school, he became increasingly drawn to chemistry, influenced by an exceptional teacher who emphasized experimentation over rote learning.
That interest deepened at home as well. Leshchiner’s older brother, just a few years ahead of him, began conducting informal chemistry experiments. Watching those early demonstrations sparked excitement and curiosity, and chemistry soon became Leshchiner’s chosen path.
He returned to Moscow to attend Moscow State University, one of the country’s most rigorous academic institutions. There, he entered the chemistry program, committing early to a demanding and immersive track. From his first year, Leshchiner joined a polymer chemistry laboratory group. Unlike many undergraduate programs, this track placed students in research labs from the start.
By the age of seventeen, Leshchiner was spending nearly every day in the lab, synthesizing compounds, running experiments, and contributing meaningfully to ongoing research. The intensity of the training rivaled graduate-level work. By his third year, he had published first-author papers, an uncommon achievement at the undergraduate level.
This early immersion shaped his scientific identity. Research was not something that came later. It formed the foundation of his education.
As part of his training, Leshchiner spent time as a visiting graduate student at MIT in Robert Langer's laboratory, a leader in biomedical engineering. There, he encountered a vibrant, interdisciplinary research culture that fosters curiosity and admiration for scientific integration. Chemists, physicists, biologists, engineers, and physicians worked side by side on problems at the interface of science and medicine.
During this period, Leshchiner worked on lipid-nanoparticle-based delivery systems for short-interfering RNA. This area would later underpin mRNA vaccine technologies. The experience expanded his vision of what chemistry could do when integrated with biology and medicine.
Following his master's and doctoral training in chemistry, Leshchiner transitioned to a different field. As high-throughput sequencing technologies emerged around 2010, he recognized an opportunity to apply quantitative and computational skills to biology on an unprecedented scale. He retrained in computational biology during his postdoctoral work at Harvard, focusing on genomics and human disease. Leshchiner transitioned to genomics, pioneering methods to analyze large-scale sequencing data and advancing cancer genomics research, including non-invasive tumor monitoring.
At the Broad Institute, Leshchiner developed techniques to detect and analyze circulating tumor DNA and RNA, revolutionizing oncology by enabling real-time, non-invasive cancer monitoring and influencing clinical practices worldwide.
“If we want to change outcomes, we have to measure what’s actually happening, in real time, in real people.”
- Ignaty Leshchiner, PhD
As Leshchiner established his own laboratory at Boston University, his interests broadened again. He began asking whether the same circulating biomarkers used in cancer could illuminate other processes, including aging and neurodegenerative disease.
His work on circulating biomarkers and leveraging tissue-specific methylation patterns aims to inspire hope and confidence in future medical advances. Leshchiner’s lab now applies these methods to Alzheimer's disease and related dementias. Current diagnostic tools often detect disease only after significant brain damage has occurred. Leshchiner aims to move diagnosis upstream by identifying molecular signals in blood that reflect early neurodegeneration.
This work on blood-based biomarkers aims to enable early diagnosis of neurodegenerative diseases like Alzheimer's, potentially transforming patient care through earlier intervention, new therapeutic developments and personalized treatment strategies.
Working with large longitudinal cohorts, including Alzheimer’s disease research centers and centenarian studies, his team analyzes blood samples collected years before diagnosis. By comparing these data to cerebrospinal fluid, imaging, and postmortem brain tissue, they seek to identify early biomarkers and distinguish molecular subtypes of dementia.
The Toffler Scholar Award supports this high-risk, high-impact effort. The funding allows Leshchiner’s lab to access rare samples, refine ultra-sensitive sequencing protocols, and generate proof-of-concept data that traditional funding mechanisms often require before offering support.
“This kind of work needs space to prove itself,” Leshchiner says. “You have to show it works before anyone is willing to back it.”
Looking ahead, Leshchiner envisions a future in which routine blood tests provide insight into brain health, aging trajectories, and disease risk, long before symptoms appear. Such tools enable earlier intervention, personalized treatment, and real-time monitoring of therapeutic response.
He also believes these approaches will reshape how scientists understand aging itself. Rather than treating aging as a uniform process, his work reveals that organs age at different rates, shaped by genetics, environment, and life history.
For Leshchiner, science has always lived at boundaries: between disciplines, between countries, and between theory and application. His career reflects a commitment to crossing those boundaries in the service of a deeper understanding.
“If we want to change outcomes,” he says, “we have to measure what’s actually happening, in real time, in real people.”